Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNTB NASDAQ:MTVA NASDAQ:MURA NASDAQ:STTK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTBConnect Biopharma$1.90-10.2%$1.75$0.51▼$2.86$105.59M-0.09117,113 shs481,658 shsMTVAMetaVia$0.67+5.2%$0.65$0.56▼$4.32$16.21M0.26306,618 shs71,912 shsMURAMural Oncology$2.08-0.2%$2.21$0.95▼$4.74$35.94M2.991.92 million shs116,084 shsSTTKShattuck Labs$1.21+19.3%$0.86$0.69▼$3.95$56.76M1.64907,567 shs13.92 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTBConnect Biopharma+2.43%+21.97%+5.50%+173.53%+31.88%MTVAMetaVia+0.44%+1.13%+4.60%-7.26%+63,699,900.00%MURAMural Oncology+0.97%+0.97%-10.34%-19.69%-37.35%STTKShattuck Labs+2.98%-0.98%+37.98%-12.93%-71.87%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCNTBConnect Biopharma2.8194 of 5 stars3.83.00.00.02.32.50.0MTVAMetaVia1.9591 of 5 stars3.50.00.00.02.70.00.6MURAMural Oncology3.3587 of 5 stars3.35.00.00.01.42.51.3STTKShattuck Labs3.1843 of 5 stars3.43.00.00.02.53.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNTBConnect Biopharma 3.50Strong Buy$7.00269.39% UpsideMTVAMetaVia 3.00Buy$7.501,019.40% UpsideMURAMural Oncology 2.50Moderate Buy$12.00478.31% UpsideSTTKShattuck Labs 2.83Moderate Buy$4.00231.95% UpsideCurrent Analyst Ratings BreakdownLatest MTVA, MURA, CNTB, and STTK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/14/2025STTKShattuck LabsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$4.00 ➝ $2.008/14/2025STTKShattuck LabsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold8/13/2025CNTBConnect BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.007/22/2025CNTBConnect BiopharmaNorthland CapmkSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/12/2025CNTBConnect BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$7.00(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNTBConnect Biopharma$26.03M4.06N/AN/A$1.28 per share1.48MTVAMetaViaN/AN/AN/AN/A$0.40 per shareN/AMURAMural OncologyN/AN/AN/AN/A$3.39 per shareN/ASTTKShattuck Labs$5.72M10.09N/AN/A$1.19 per share1.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNTBConnect Biopharma-$15.63MN/A0.00N/AN/AN/AN/AN/A9/5/2025 (Estimated)MTVAMetaVia-$27.59MN/A0.00N/AN/AN/A-212.00%-107.21%11/6/2025 (Estimated)MURAMural Oncology-$128.51M-$8.59N/AN/AN/AN/A-107.76%-87.57%11/12/2025 (Estimated)STTKShattuck Labs-$75.41M-$1.21N/AN/AN/AN/A-81.80%-71.46%11/13/2025 (Estimated)Latest MTVA, MURA, CNTB, and STTK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/5/2025H1 2025CNTBConnect Biopharma-$0.22N/AN/AN/AN/AN/A8/14/2025Q2 2025STTKShattuck Labs-$0.25-$0.24+$0.01-$0.24N/AN/A8/7/2025Q2 2025MTVAMetaVia-$0.32-$0.26+$0.06-$0.26N/AN/A8/4/2025Q2 2025MURAMural Oncology-$1.13-$1.77-$0.64-$2.78N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCNTBConnect BiopharmaN/AN/AN/AN/AN/AMTVAMetaViaN/AN/AN/AN/AN/AMURAMural OncologyN/AN/AN/AN/AN/ASTTKShattuck LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNTBConnect Biopharma0.017.247.24MTVAMetaViaN/A2.082.08MURAMural OncologyN/A2.872.87STTKShattuck LabsN/A10.2510.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNTBConnect Biopharma58.72%MTVAMetaVia1.37%MURAMural Oncology80.21%STTKShattuck Labs58.74%Insider OwnershipCompanyInsider OwnershipCNTBConnect Biopharma22.60%MTVAMetaVia0.80%MURAMural Oncology2.20%STTKShattuck Labs12.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNTBConnect Biopharma11055.72 million43.13 millionOptionableMTVAMetaVia824.20 million24.00 millionN/AMURAMural Oncology11917.32 million16.94 millionOptionableSTTKShattuck Labs10047.90 million42.16 millionOptionableMTVA, MURA, CNTB, and STTK HeadlinesRecent News About These CompaniesShattuck Labs (NASDAQ:STTK) Director Orbimed Advisors Llc Purchases 6,306,127 Shares of StockSeptember 3 at 4:13 AM | americanbankingnews.comShattuck Labs (NASDAQ:STTK) Director Mona Ashiya Buys 6,306,127 SharesSeptember 3 at 4:07 AM | insidertrades.comOrbiMed Advisors buys Shattuck Labs (STTK) shares worth $5.47 millionSeptember 3 at 3:38 AM | investing.comAshiya Mona buys Shattuck Labs (STTK) shares worth $5.47 millionSeptember 3 at 3:38 AM | investing.comShattuck Labs Closes $103M Private Placement DealAugust 26, 2025 | msn.comShattuck Labs Secures $103 Million in Private Placement to Advance SL-325 for Autoimmune Diseases and Appoints New Board MembersAugust 26, 2025 | quiverquant.comQShattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of DirectorsAugust 26, 2025 | globenewswire.comShattuck Labs, Inc.: Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel DiseaseAugust 22, 2025 | finanznachrichten.deShattuck Labs says IND for SL-325 for treatment of IBD in effectAugust 22, 2025 | msn.comShattuck Labs Reports Q2 2025 Financial ResultsAugust 22, 2025 | msn.comShattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel DiseaseAugust 21, 2025 | globenewswire.comShattuck Labs raises up to $103M to fund therapeutic antibody developmentAugust 19, 2025 | ncbiotech.orgNShattuck Labs price target lowered to $2 from $4 at LeerinkAugust 14, 2025 | msn.comShattuck Labs Submits IND Application for SL-325; Phase 1 Trial in Healthy Volunteers Expected to Begin Q3 2025August 14, 2025 | quiverquant.comQShattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business HighlightsAugust 14, 2025 | globenewswire.comShattuck Labs expects $103 million from private placingAugust 6, 2025 | thepharmaletter.comTShattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 MillionAugust 5, 2025 | globenewswire.comShattuck Labs Elects Directors, Approves Auditor at MeetingJuly 15, 2025 | tipranks.comShattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and MetabolismJuly 2, 2025 | globenewswire.comShattuck Labs, Inc. (STTK) - Yahoo FinanceJune 28, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMTVA, MURA, CNTB, and STTK Company DescriptionsConnect Biopharma NASDAQ:CNTB$1.90 -0.22 (-10.19%) As of 12:56 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.MetaVia NASDAQ:MTVA$0.67 +0.03 (+5.18%) As of 12:37 PM EasternMetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.Mural Oncology NASDAQ:MURA$2.08 -0.01 (-0.24%) As of 01:05 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.Shattuck Labs NASDAQ:STTK$1.20 +0.20 (+19.31%) As of 01:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season Loop Industries Insiders Buy Stock, Signal Confidence in Outlook Joby Aviation's Pullback: A Gift for Investors Who See the Future Opera Limited Stock Set to End 2025 on a High Note Kohl’s Stock Rebound Faces a Showdown With Short Sellers Tesla Bulls Need to Tread Very Carefully Right Now Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
